<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-7459</journal-id>
<journal-title><![CDATA[Horizonte sanitario]]></journal-title>
<abbrev-journal-title><![CDATA[Horiz. sanitario]]></abbrev-journal-title>
<issn>2007-7459</issn>
<publisher>
<publisher-name><![CDATA[Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-74592019000100057</article-id>
<article-id pub-id-type="doi">10.19136/hs.a18n1.2402</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Reacciones adversas evitables graves por antivirales. Sistema Cubano de Farmacovigilancia, 2008-2017]]></article-title>
<article-title xml:lang="en"><![CDATA[Serious adverse reactions avoidable by antivirals. Cuban Pharmacovigilance System, 2008-2017]]></article-title>
<article-title xml:lang="pt"><![CDATA[Reações adversas severas prevenidas por antivirais. Sistema cubano de farmacovigilancia, 2008-2017]]></article-title>
<article-title xml:lang="fr"><![CDATA[Réactions indésirables graves évitable par les antiviraux. Systeme cubain de pharmacovigilance, 2008-2017]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales Pérez]]></surname>
<given-names><![CDATA[Mayasil]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Milian]]></surname>
<given-names><![CDATA[Ana Julia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Ciencias Médicas de La Habana Departamento Farmacología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Escuela Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<volume>18</volume>
<numero>1</numero>
<fpage>57</fpage>
<lpage>66</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-74592019000100057&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-74592019000100057&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-74592019000100057&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Caracterizar las reacciones adversas graves evitables por antivirales presentes en el Sistema Cubano de Farmacovigilancia durante los años 2008 al 2017.  Material y métodos: Investigación cuantitativa, observacional y descriptiva; enmarcada dentro de los estudios de farmacovigilancia, con un diseño de serie de casos. El universo conformado por las notificaciones de reacciones adversas graves evitables provocadas estos fármacos. Se utilizaron variables como: reacción adversa identificada, grupo de edad, sexo, fármaco antiviral, frecuencia y causas de evitabilidad.  Resultados: Las reacciones adversas evitables graves a los antivirales se comportaron a ritmo irregular que muestra tendencia al incremento. Predominaron en hombres (77.8%) y en adultos (94.4%). Zidovudina (44.4%) y nevirapina (38.9%) muestraron la mayor cantidad de reportes, relacionados con la aparición de anemia y síndrome de Stevens Johnson. Los médicos reportaron el 72.2% de los casos. Las reacciones encontradas se describen como frecuentes. Las interacciones medicamentosas (61.1%) fue la principal causa de evitabilidad.  Conclusiones: La caracterización de las reacciones adversas graves evitables a los antivirales permitió identificar que las mismas fueron frecuentes, producidas por antirretrovirales y presentadas hombres adultos; siendo la anemia y síndrome de Stevens Johnson las más frecuentes. Las causas de evitabilidad identificadas con mayor frecuencia responden a errores de la prescripción.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Object: To characterize the serious adverse reactions avoidable by antivirals present in the Cuban Pharmacovigilance System during the years 2008 to 2017.  Materials and methods: Quantitative, observational and descriptive research; framed within the pharmacovigilance studies, with a case series design. The sample conformed by the reports of avoidable serious adverse reactions caused by these drugs. Variables were: identified adverse reaction, age group, sex, antiviral drug, frequency and causes of preventability.  Results: Severe avoidable adverse reactions to antivirals were presented at an irregular level that shows a tendency to increase. They predominated in men (77.8%) and in adults (94.4%). Zidovudine (44.4%) and nevirapine (38.9%) showed the highest number of reports, related to the appearance of anemia and Stevens-Johnson syndrome. The doctors reported 72.2% of the cases. The reactions found are described as frequent. Drug interactions (61.1%) was the main cause of preventability.  Conclusions: The characterization of the serious adverse reactions avoidable to the antivirals allowed to identify that they were in their majority produced by antiretroviral and occurred mainly in adult men; anemia and Stevens-Johnson syndrome were the most frequent. The causes of preventability identified with greater frequency correspond to errors of the prescription.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Objetivo: Saracterizar as reações adversas graves evitáveis por antivirais presentes no Sistema Cubano de Farmacovigiláncia durante os anos de 2008 a 2017.  Materiais e métodos: Pesquisa quantitativa, observacional e descritiva; enquadrada no ámbito de estudos de farmacovigiláncia, com um desenho de estudos de casos. O universo foi constituido pelos relatórios das notificações de reações adversas graves causadas por esses medicamentos. Foram utilizadas variáveis, tais como: reacjao adversa identificada, grupo etário, sexo, fármaco antiviral, frequência e causas de prevenjao.  Resultados: Reações adversas severas preveníveis por antivirais surgem a um ritmo irregular mostrando um aumento crescente. Predominaram em homens (77,8%) e em adultos (94,4%). Zidovudina (44,4%) e nevirapina (38,9%) apresentaram o maior número de relatos, relacionados ao aparecimento de anemia e síndrome de Stevens Johnson. Os médicos relataram 72,2% dos casos. As reações encontradas são descritas como frequentes. As interajoes medicamentosas (61,1%) foram a principal causa da prevenção.  Conclusões: A caracterização de reações adversas graves, preveniveis por antivirais permitiram identificar que eram frequentes, produzidos por anti-retrovirais e apresentados em homens adultos; sendo a anemia e a síndrome de Stevens Johnson as mais frequentes. As causas mais frequentemente identificadas de prevenção demonstram erros de prescrição.]]></p></abstract>
<abstract abstract-type="short" xml:lang="fr"><p><![CDATA[Résumé  Objectif: Caractériser les effets indésirables graves évitables par les antiviraux présents dans le systéme cubain de pharmacovigilance pendant les années 2008 á 2017.  Matériaux et méthodes: Recherche quantitative, observationnelle et descriptive; encadré dans les études de pharmacovigilance, avec une conception de série de cas. L&#8217;échantillon était conforme aux rapports d&#8217;effets indésirables graves évitables provoqués par ces médicaments. Les variables utilisées étaient réaction indésirable identifiée, groupe d&#8217;áge, sexe, médicament antiviral, fréquence et causes de prévention.  Résultats: Les réactions indésirables évitables tombes aux antiviraux se sont comportées á un rythme irrégulier qui a tendance á augmenter. Ils prédominaient chez les hommes (77,8%) et chez les adultes (94,4%). La zidovudine (44,4%) et la névirapine (38,9%) présentaient le plus grand nombre de signalements, liés á l&#8217;apparition de l&#8217;anémie et au syndrome de Stevens-Johnson. Les médecins rapportent 72.2% des cas. Les réactions trouvées sont souvent déclinées. Les interactions médicamenteuses (61,1%) étaient la principale cause évitable.  Conclusion: La caractérisation des effets indésirables graves évitables antiviraux a permis d&#8217;identifier qu&#8217;ils étaient produits principalement par les antirétroviraux et se produisaient principalement chez les hommes adultes; l&#8217;anémie et le syndrome de Stevens-Johnson étaient les plus fréquents. Les causes évitables identifiées généralement correspondent á des erreurs de prescription.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Reacciones adversas graves]]></kwd>
<kwd lng="es"><![CDATA[antivirales]]></kwd>
<kwd lng="es"><![CDATA[antirretrovirales]]></kwd>
<kwd lng="es"><![CDATA[evitabilidad]]></kwd>
<kwd lng="en"><![CDATA[Adverse reactions]]></kwd>
<kwd lng="en"><![CDATA[antiviral treatment]]></kwd>
<kwd lng="en"><![CDATA[antiretrovirals]]></kwd>
<kwd lng="en"><![CDATA[preventability]]></kwd>
<kwd lng="pt"><![CDATA[Reações adversas]]></kwd>
<kwd lng="pt"><![CDATA[tratamento antiviral]]></kwd>
<kwd lng="pt"><![CDATA[anti-retrovirais]]></kwd>
<kwd lng="pt"><![CDATA[prevenção]]></kwd>
<kwd lng="fr"><![CDATA[Réactions indésirables graves]]></kwd>
<kwd lng="fr"><![CDATA[traitement antiviral]]></kwd>
<kwd lng="fr"><![CDATA[les antirétroviraux]]></kwd>
<kwd lng="fr"><![CDATA[évitabilité]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Departamento de Salud y Servicios Humanos de EE.UU</collab>
<article-title xml:lang=""><![CDATA[Medicamentos contra el VIH y sus efectos secundarios]]></article-title>
<source><![CDATA[infoSIDA]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales-Pérez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[García-Milián]]></surname>
<given-names><![CDATA[AJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxicity by antiviral drugs, a hidden reality]]></article-title>
<source><![CDATA[Rev Sal Quintana Roo]]></source>
<year>2015</year>
<volume>8</volume>
<numero>31</numero>
<issue>31</issue>
<page-range>23-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-del-Sol]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[García-Milian]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso-Carbonell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Reid-Armenteros]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumo y costo de medicamentos antirretrovirales utilizados para el tratamiento de pacientes con VIH/sida La Habana, 2009-2013.]]></article-title>
<source><![CDATA[INFODIR Bioméd]]></source>
<year>2014</year>
<volume>18</volume>
<page-range>27-40</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Estadísticas mundiales sobre el VIH. ONUSIDA</collab>
<source><![CDATA[Hoja informativa del día mundial del SIDA]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Organización Panamericana de la Salud</collab>
<collab>Red Panamericana de la armonización de la reglamentación farmacéutica</collab>
<collab>grupo de trabajo de buenas prácticas de farmacovigilancia</collab>
<source><![CDATA[Buenas prácticas de farmacovigilancia para las Américas]]></source>
<year>2008</year>
<publisher-name><![CDATA[OPS: PARF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Normas y procedimientos de trabajo del Sistema Cubano de Farmacovigilancia]]></source>
<year>2011</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Unidad Coordinadora Nacional de Farmacovigilancia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francisco]]></surname>
<given-names><![CDATA[Rojas-Ochoa]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigación sobre consumo de medicamentos. Experiencia cubana]]></article-title>
<source><![CDATA[Rev. Cubana Salud Pública]]></source>
<year>2014</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morillo-Verdugo]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco-Ramos]]></surname>
<given-names><![CDATA[JR.]]></given-names>
</name>
<name>
<surname><![CDATA[Abdel-Kader]]></surname>
<given-names><![CDATA[Martin L.]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez-de-Sotomayor]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El reto del envejecimiento y la complejidad farmacoterapeútica en el paciente VIH+]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bastida]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Grau]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Tuset]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[de Lazzari]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polifarmacia e interacciones farmacológicas potenciales en una población envejecida con infección por el VIH]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Unidad Coordinadora Nacional de Farmacovigilancia</collab>
<collab>Dirección de medicamentos</collab>
<collab>Departamento de Farmacoepidemiología</collab>
<source><![CDATA[Balance anual 2014. Sistema Cubano de Farmacovigilancia]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Rodríguez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Duque-Vizcaíno]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Peraza]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonso-Orta]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez-López]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta-Reynaldo]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Notificaciones espontáneas de sospechas de reacciones adversas a los medicamentos. Instituto &#8220;Pedro Kouri&#8221;]]></article-title>
<source><![CDATA[Rev Cubana Farm]]></source>
<year>2016</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53-69</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schumock]]></surname>
<given-names><![CDATA[GT.]]></given-names>
</name>
<name>
<surname><![CDATA[Thorton]]></surname>
<given-names><![CDATA[JP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Focusing on preventability of adverse drug reactions]]></article-title>
<source><![CDATA[Hosp Pharm]]></source>
<year>1992</year>
<volume>27</volume>
<page-range>538</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero-López]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso-Hernández]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Maderuelo-Fernández]]></surname>
<given-names><![CDATA[JA.]]></given-names>
</name>
<name>
<surname><![CDATA[Ceruelo-Bermejo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Gil Hurlé]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Rodríguez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia y factores asociados a los acontecimientos adversos prevenibles por medicamentos que causan el ingreso hospitalario.]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2006</year>
<volume>30</volume>
<page-range>161-70</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Gestión de la base de datos del sistema cubano de Farmacovigilancia. PNO: 004.]]></source>
<year>2008</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallego-Muñoz]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero-Navarro]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzo-Martin]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[importancia de la notificación espontanea de reacciones adversas asociadas a fármacos antirretrovirales]]></article-title>
<source><![CDATA[Enf Clin]]></source>
<year>2017</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>138-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Roque]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Respuesta clínica e inmunovirológica a la terapia antirretroviral combinada al año en una cohorte de pacientes con diagnóstico de VIH atendidos en el hospital Dr. Roberto Calderón Gutiérrez en el periodo enero-diciembre 2015.]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Plan estratégico nacional para la prevención y el control de las ITS y el VIH/SIDA, 2014-2018]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez-Guerrero]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Núñez-Núñez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Castañeda-Macías]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Sandoval-Fernández-del-Castillo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interacciones potenciales en una cohorte de pacientes VIH positivos de edad avanzada]]></article-title>
<source><![CDATA[Farm Hops]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[DM.]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MA.]]></given-names>
</name>
<name>
<surname><![CDATA[Furones]]></surname>
<given-names><![CDATA[JA.]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[AJ.]]></given-names>
</name>
</person-group>
<source><![CDATA[Formulario Nacional de Medicamentos]]></source>
<year>2014</year>
<edition>4</edition>
<page-range>195-213</page-range><publisher-loc><![CDATA[Cuba ]]></publisher-loc>
<publisher-name><![CDATA[Ecimed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>Agencia española de medicamentos y productos sanitarios</collab>
<source><![CDATA[Ficha técnica Aciclovir Aristo 50 mg/g crema EFG]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frometa-Báez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonso-Orta]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Rodríguez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reacciones adversas a los antirretrovirales en pacientes VIH/SIDA. Instituto Pedro Kouri, 2015.]]></article-title>
<source><![CDATA[Rev Cub Tecnolog Salud]]></source>
<year>2016</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jimenez-López]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Fariña]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Gálvez-González]]></surname>
<given-names><![CDATA[AM.]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonso-Orta]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Lara-Bastanzuri]]></surname>
<given-names><![CDATA[MC.]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo-Barbado]]></surname>
<given-names><![CDATA[DM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicamentos notificados como productores de reacciones adversas graves en Cuba en un periodo de diez años]]></article-title>
<source><![CDATA[Rev Cuban Salud Pub]]></source>
<year>2014</year>
<volume>40</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>263-75</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serrano-López-de-las-Hazas]]></surname>
<given-names><![CDATA[JI.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interacciones farmacológicas de los nuevos antirretrovirales]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2011</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>36-43</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manzardo]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Tuset]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Miró]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
<name>
<surname><![CDATA[Gatelll]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interacciones graves o potencialmente letales entre antirretrovirales y otros medicamentos.]]></article-title>
<source><![CDATA[Enf Infecc Microbiol Clin]]></source>
<year>2015</year>
<volume>33</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>e15-30</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilead]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet &#8220;Quad&#8221; HIV Regimen.]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Mcgoogan]]></surname>
<given-names><![CDATA[JC.]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[CX.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in China: a nationwide, retrospective cohort study.]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2017</year>
<volume>XX</volume>
<numero>00</numero>
<issue>00</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<collab>Departamento de Salud y Servicios Humanos de EE.UU</collab>
<article-title xml:lang=""><![CDATA[tratamiento del VIH: conceptos básicos]]></article-title>
<source><![CDATA[infoSIDA]]></source>
<year>2018</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
